The company maintains a clean capital structure with a debt-to-equity ratio of 0.00, though accumulated deficits have deteriorated to -$810.8 million as of 2026Q1 due to sustained development costs.
| Total Current Assets | 658.04M | 675.7M | 863.41M | 346.79M | 477.98M | 66.96M | 1.87M |
| Cash & Short-Term Investments | 636.11M | 636.24M | 834.19M | 340.45M | 467.73M | 60.38M | 1.37M |
| Cash Only | 457.61M | 490M | 771.74M | 340.45M | 467.73M | 60.38M | 1.37M |
| Short-Term Investments | 178.5M | 146.24M | 62.45M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.22M | 23.15M | 21.3M | 1.88M | 0 | 0 | 0 |
| Days Sales Outstanding | 208.75 | 375.53 | 170.67 | 48.73 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.34M | 1.32M | 0 | 0 | 2.07M | 4.88M | 0 |
| Total Non-Current Assets | 74.6M | 93.58M | 1.21M | 306K | 518K | 1.03M | 138M |
| Property, Plant & Equipment | 400K | 568K | 673K | 101K | 154K | 216.08K | 0 |
| Fixed Asset Turnover | 41.85x | 39.62x | 67.70x | 139.50x | 666.84x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 375K | 407K | 534K | 170K | 208K | 0 | 0 |
| Long-Term Investments | 97.26M | 0 | 0 | 0 | 0 | 0 | 138M |
| Other Non-Current Assets | 73.82M | 92.61M | 0 | 35K | 156K | 816.56K | 0 |
| Total Assets | 732.64M | 769.28M | 864.62M | 347.1M | 478.5M | 67.99M | 139.87M |
| Asset Turnover | 0.03x | 0.03x | 0.05x | 0.04x | 0.21x | - | - |
| Asset Growth % | 140.03% | -11.03% | 149.1% | -27.46% | 603.79% | -51.39% | - |
| Total Current Liabilities | 67.42M | 85.79M | 106.92M | 49.9M | 36.06M | 11.24M | 236.52K |
| Accounts Payable | 8.09M | 8.97M | 4.74M | 16.92M | 11.85M | 7.07M | 162.48K |
| Days Payables Outstanding | 4.34K | 55.49K | - | - | - | - | - |
| Short-Term Debt | 23K | 136K | 246K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 7.97M | 3.99M | 6.01M | 8.94M | 0 | 0 | 0 |
| Other Current Liabilities | 55.32M | 72.69M | 91.03M | 15.96M | 18.02M | 0 | 74.04K |
| Current Ratio | 9.76x | 7.88x | 8.08x | 6.95x | 13.26x | 5.96x | 7.90x |
| Quick Ratio | 9.76x | 7.88x | 8.08x | 6.95x | 13.26x | 5.96x | 7.90x |
| Cash Conversion Cycle | -4.13K | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 66K | 202K | 8.81M | 12.37M | 126.24K | 12.17M |
| Long-Term Debt | 0 | 66K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 103K | 0 | 202K | 0 | 60K | 126.24K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 7.79M | 12.31M | 0 | 12.17M |
| Total Liabilities | 67.42M | 85.85M | 107.12M | 58.7M | 48.43M | 11.36M | 12.41M |
| Total Debt | 23K | 202K | 448K | 60K | 126K | 186.51K | 0 |
| Net Debt | -457.58M | -489.8M | -771.29M | -340.39M | -467.6M | -60.19M | -1.37M |
| Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.13x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -26.02x | -77.86x | -100.67x | - |
| Total Equity | 665.22M | 683.43M | 757.5M | 288.39M | 430.07M | 56.63M | 127.46M |
| Equity Growth % | 168.9% | -9.78% | 162.66% | -32.94% | 659.49% | -55.57% | - |
| Book Value per Share | 5.49 | 5.97 | 8.03 | 3.51 | 22.68 | 3.19 | 7.18 |
| Total Shareholders' Equity | 665.22M | 683.43M | 757.5M | 288.39M | 430.07M | 56.63M | 127.46M |
| Common Stock | 14.59M | 14.28M | 13.44M | 10.17M | 10.05M | 128.51K | 122.46M |
| Retained Earnings | -810.83M | -762.39M | 0 | -316.97M | -140.04M | -39.44M | 41.45K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.22M | 4.79M | 4.47M | 4.42M | 4.42M | 672.13K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial outcomes
As reported in financial statements, NAMS's total assets have declined from a peak of $864.6M in 2024Q4 to $732.6M in 2026Q1, reflecting the ongoing consumption of capital to fund late-stage clinical trials while the company lacks a recurring, self-sustaining commercial revenue stream to offset these expenditures.
The downward trajectory in total assets appears to be a direct consequence of the company's R&D-heavy business model, which necessitates consistent cash outflows. Investors should monitor whether this asset depletion accelerates as the company approaches critical data readouts, as the current trajectory suggests a finite runway that will eventually require either commercial success or external financing.
Based on the most recent quarterly data, NAMS maintains a cash position of $457.6M, which provides a current ratio of 9.76, suggesting that the company possesses a substantial liquidity buffer to support its ongoing Phase 3 cardiovascular outcomes trials through the near-term data release cycle.
The high current ratio indicates that the firm is well-positioned to meet its short-term obligations without immediate liquidity stress. However, the rapid decline in cash from $771.7M in 2024Q4 highlights the intensity of the burn rate, implying that the current liquidity cushion is a temporary bridge rather than a permanent state of financial health.
According to the company's balance sheet, retained earnings have deteriorated to -$810.8M as of 2026Q1, a trend that underscores the significant, non-recoverable investment required to advance the obicetrapib program through the regulatory and clinical hurdles necessary for potential market entry in the cardiovascular space.
The persistent negative retained earnings are typical for a clinical-stage biotechnology firm and serve as a proxy for the total capital invested in R&D to date. This accumulation of losses suggests that equity value is currently tied entirely to the future probability of success for the lead candidate rather than any tangible book value.
While the company reports a negligible debt-to-equity ratio of 0.00, this headline figure may be misleading, as it ignores the substantial off-balance-sheet operational commitments and the inherent financial risk associated with the company's reliance on milestone-based licensing revenue to sustain its long-term clinical development program.
The absence of traditional debt suggests that the company has avoided interest-bearing leverage, yet the reliance on equity-based funding and milestone payments creates a different form of financial vulnerability. Investors should consider that the lack of debt does not mitigate the binary risk of clinical failure, which remains the primary threat to the company's long-term solvency.
Quick answers to the most common questions about buying NAMS stock.
As of 2025, NewAmsterdam Pharma Company N.V. (NAMS) had total assets of $769.3M including $675.7M in current assets.
NewAmsterdam Pharma Company N.V. (NAMS) carries total debt of $0.2M, offset by $636.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
NewAmsterdam Pharma Company N.V. (NAMS) has total shareholders' equity (book value) of $683.4M ($5.97 book value per share). Book value represents the net worth of the company belonging to common stock holders.
NewAmsterdam Pharma Company N.V. (NAMS) reported a current ratio of 7.88x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.